Treatment-Stratified Immune–Inflammatory Trajectories and Early Response in Patients with Hepatocellular Carcinoma Receiving Systemic Therapy
Background: Systemic therapy outcomes in hepatocellular carcinoma (HCC) remain heterogeneous, and treatment selection is still largely guided by clinical eligibility rather than dynamic biologic response. We evaluated whether accessible standard-of-care immunophenotypic and immune–inflammatory markers, tumor-marker kin...